Silo Pharma Inc. (NASDAQ: SILO) has received a Notice of Allowance from the Canadian Intellectual Property Office (CIPO) for a patent application covering its lead asset, SPC-15, an intranasal 5-HT4 receptor agonist designed to treat post-traumatic stress disorder (PTSD) and other stress-induced psychiatric disorders. The announcement, made public today, marks a significant step in the company's efforts to secure intellectual property protection for its most advanced therapeutic candidate in key global markets.
The Canadian patent allowance follows the recent grant of a European patent covering the same core invention, and corresponding intellectual property is either granted or advancing in multiple international markets. Silo holds an exclusive license to the Canadian patent application through a broader agreement with Columbia University, which grants the company rights to further develop, manufacture, and commercialize SPC-15 globally.
SPC-15 is being developed as a novel treatment for PTSD, a condition that affects millions worldwide and has seen limited therapeutic innovation. By targeting the 5-HT4 receptor, the drug aims to address the underlying neurobiological mechanisms of stress-induced psychiatric disorders. Silo plans to pursue the FDA's streamlined 505(b)(2) regulatory pathway for SPC-15, a route that could potentially shorten clinical timelines and reduce development costs compared to traditional new drug applications. This strategy may accelerate the path to market for a therapy that addresses a significant unmet medical need.
The importance of this development lies in the growing recognition of PTSD as a major public health issue, particularly among military veterans and survivors of trauma. Current treatment options are often limited by efficacy and tolerability issues, leaving many patients without adequate relief. If approved, SPC-15 could offer a new, non-invasive treatment option administered via intranasal delivery, which may improve patient compliance and onset of action.
Silo Pharma is a developmental-stage biopharmaceutical company with a diverse pipeline targeting underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The company's portfolio includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets for Alzheimer's disease and multiple sclerosis. Research is conducted in collaboration with leading academic institutions, including Columbia University.
The Canadian patent allowance strengthens Silo's intellectual property position and supports its commercial strategy in North America. As the company progresses SPC-15 through regulatory pathways, this milestone reinforces its commitment to bringing innovative treatments to patients in need. For more information about Silo Pharma and its pipeline, visit the company's website at silopharma.com. The full press release is available at https://ibn.fm/L3Jm4.
